Literature DB >> 9093730

Docetaxel and interstitial pulmonary injury.

M Merad1, A Le Cesne, P Baldeyrou, B Mesurolle, T Le Chevalier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9093730     DOI： 10.1023/a:1008226416896

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

1.  Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.

Authors:  Masahiro Tsuboi; Thierry Le Chevalier
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.

Authors:  Min-Young Lee; Ki Sun Jung; Hae Su Kim; Ji Yun Lee; Sung Hee Lim; Moonjin Kim; Hyun Ae Jung; Sung Min Kim; Jong Mu Sun; Myung-Ju Ahn; Jeeyun Lee; Se Hoon Park; Seong Yoon Yi; In Gyu Hwang; Sang-Cheol Lee; Hee Kyung Ahn; Do Hyoung Lim; Soon Il Lee; Keon Woo Park
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

3.  Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan.

Authors:  Moon Jin Kim; Gyeong-Won Lee; Jong Woo Seo; Hyun-Jung Kim; Sung-Nam Lim; Cheolwon Suh
Journal:  Invest New Drugs       Date:  2010-05-21       Impact factor: 3.850

4.  Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.

Authors:  Emilio Esteban; Noemi Villanueva; Isabel Muñiz; Yolanda Fernández; Joaquin Fra; Maria Luque; Paula Jiménez; Beatriz Llorente; Marta Capelan; José M Vieitez; Enrique Estrada; José M Buesa; Angel Jiménez-Lacave
Journal:  Invest New Drugs       Date:  2007-09-05       Impact factor: 3.850

5.  Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.

Authors:  Kwang Min Kim; Ho-Cheol Kim; Kyung-Nyeo Jeon; Hoon-Gu Kim; Jung Hun Kang; Jong Ryeal Hahm; Gyeong-Won Lee
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

6.  Pulmonary toxicity in patients receiving docetaxel chemotherapy.

Authors:  Perran F Yumuk; Umut Kefeli; Berrin Ceyhan; Faysal Dane; Basak T Eroglu; Mahmut Gumus; Devrim Cabuk; Gul Basaran; Ufuk Abacioglu; Nazım S Turhal
Journal:  Med Oncol       Date:  2009-12-25       Impact factor: 3.064

Review 7.  Diagnosis and management of drug-associated interstitial lung disease.

Authors:  N L Müller; D A White; H Jiang; A Gemma
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

Review 8.  Understanding the mechanisms of drug-associated interstitial lung disease.

Authors:  T Higenbottam; K Kuwano; B Nemery; Y Fujita
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

Review 9.  Interstitial lung disease associated with drug therapy.

Authors:  P Camus; S Kudoh; M Ebina
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

10.  Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management.

Authors:  P Camus
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.